• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Forest Laboratories appoints executive team members

Forest Laboratories appoints executive team members

December 11, 2013
CenterWatch Staff

Forest Laboratories, a specialty pharmaceutical company focused on the U.S., has announced appointments to its executive leadership team as part of its plans to flatten and broaden the organization during Project Rejuvenate.

"We are announcing an important step to rejuvenate our company by creating the first Forest executive team with broad leadership responsibilities, a sharp focus and clear accountability for driving sustainable growth," said Brent Saunders, CEO and president Forest Laboratories.

Elaine Hochberg has been appointed executive vice president, international, strategic planning and government affairs. Bill Meury was appointed executive vice president, sales and marketing. Frank Perier, Jr., now is executive vice president, chief financial officer. Marco Taglietti, M.D., is executive vice president, drug R&D, and chief medical officer. Bob Bailey is senior vice president, chief legal officer, general counsel and corporate secretary. Alex Kelly has been appointed senior vice president, chief communications and investor relations officer. Sally Paull was appointed senior vice president, human resources. Kevin Walsh now is senior vice president, operations. Joe Zimmerman has been appointed senior vice president, chief compliance officer.

David Solomon, senior vice president, corporate development and strategic planning, will become senior advisor to the chief executive officer responsible for business development and alliance management on a transitional basis.

"Solomon played an instrumental role in driving and executing our company's successful Next 9 Strategy, which has given us a solid foundation of future growth drivers," said Saunders. "During his transition period, I will draw on David's experience and counsel as we embark on our company's next chapter."

The next step in Project Rejuvenate is for the Forest executive team to design and staff their respective teams in a manner consistent with the principles of flattening and broadening the organization.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing